In this interview we speak to Jonathan Kurtis (Brown University, RI, USA) about the discovery of a parasite protein that provides new insights into how malaria regulates infection levels within its host, along with new possibilities for a broadly effective vaccine and a new class of antimalarial drugs.
The first clinical trial assessing two triple artemisinin-based combination therapies (TACTs) for treating malaria has suggested these are effective and present no safety concerns.
Upon investigating links between the risk of malaria in developing countries and the products demanded by consumers worldwide, researchers have estimated that a significant fraction of the malaria risk in deforestation hotspots is driven by the international trade of products.
The WHO has published 2019’s World Malaria Report, providing an update on global trends and highlighting pregnant women and children as particularly at-risk groups.
Published in Nature, new research elucidates the mechanism behind malarial resistance to piperaquine and suggests how this knowledge could be used to combat its spread.
A report published by The Lancet Commission has suggested that malaria eradication can be achieved as early as 2050.
Researchers recently profiled the single-cell transcriptomes of thousands of individual parasites to provide the first high-resolution atlas of malaria parasite gene expression across the lifecycle.
B. Joanne Power gives us a summary of the conference highlights from BioMalPar XV, including new strategies for vector control and new insights into the malaria parasite.
Multidrug resistance to two antimalarials, used in combination as a first-line therapy, has been found using genomic surveillance to be rapidly spreading throughout Asia.
New research has assessed a genetically engineered fungus for the control of malaria mosquitoes in the first semi-field trial, demonstrating that populations were reduced by more than 99%.